# A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

> **NCT03719326** · PHASE1 · COMPLETED · sponsor: **Arcus Biosciences, Inc.** · enrollment: 35 (actual)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Etrumadenant
- **DRUG:** IPI-549
- **DRUG:** Pegylated liposomal doxorubicin (PLD)
- **DRUG:** nanoparticle albumin-bound paclitaxel (NP)

## Key facts

- **NCT ID:** NCT03719326
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-15
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-02
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03719326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03719326, "A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03719326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*